Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Exelixis Inc (EXEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 21.00 thousand shares for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-10
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-01-03 was 24.00K shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-27 was 0.00 shares, a 100.00% decline year-over-year.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-28 was 0.00 shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-29 was 100.00K shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 21.00K shares, a 83.06% decline from fiscal 2025.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 124.00K shares, a 65.27% decline from fiscal 2023.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 357.00K shares, a 39.39% decline from fiscal 2022.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 589.00K shares, a 77.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-01-02 | 21.00K shares 10-K · filed 2026-02-10 | |||
| 2025-01-03 | 24.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | 24.00K shares derived: sum of 2 quarters · filed 2025-02-11 | 24.00K shares derived: sum of 3 quarters · filed 2025-02-11 | 124.00K shares 10-K · filed 2025-02-11 |
| 2024-09-27 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 0.00 shares derived: sum of 2 quarters · filed 2024-10-29 | 100.00K shares 10-Q · filed 2024-10-29 | 99.77K shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-28 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 100.00K shares 10-Q · filed 2024-08-06 | 99.77K shares derived: sum of 3 quarters · filed 2024-08-06 | 259.77K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-29 | 100.00K shares 10-Q · filed 2024-04-30 | 99.77K shares derived: sum of 2 quarters · filed 2024-04-30 | 259.77K shares derived: sum of 3 quarters · filed 2024-04-30 | |
| 2023-12-29 | -233.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | 159.77K shares derived: sum of 2 quarters · filed 2024-02-06 | 357.00K shares 10-K · filed 2024-02-06 | |
| 2023-09-29 | 160.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 357.23K shares 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | 197.23K shares 10-Q · filed 2023-08-01 | |||
| 2022-12-30 | 138.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | 1.24K shares derived: sum of 2 quarters · filed 2023-02-07 | 355.52K shares derived: sum of 3 quarters · filed 2023-02-07 | 589.00K shares 10-K · filed 2023-02-07 |
| 2022-09-30 | 1.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 355.39K shares derived: sum of 2 quarters · filed 2022-11-01 | 588.86K shares 10-Q · filed 2022-11-01 | |
| 2022-07-01 | 354.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 587.76K shares 10-Q · filed 2022-08-09 | ||
| 2022-04-01 | 233.48K shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 2.57M shares 10-K · filed 2022-02-18 | |||
| 2021-01-01 | 447.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | 797.68K shares derived: sum of 2 quarters · filed 2021-02-11 | 1.37M shares derived: sum of 3 quarters · filed 2021-02-11 | 1.64M shares 10-K · filed 2021-02-11 |
| 2020-10-02 | 350.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 918.52K shares derived: sum of 2 quarters · filed 2020-11-05 | 1.19M shares 10-Q · filed 2020-11-05 | 1.46M shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-07-03 | 567.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 839.32K shares 10-Q · filed 2020-08-06 | 1.11M shares derived: sum of 3 quarters · filed 2020-08-06 | 1.35M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-04-03 | 271.37K shares 10-Q · filed 2020-05-05 | 540.08K shares derived: sum of 2 quarters · filed 2020-05-05 | 781.20K shares derived: sum of 3 quarters · filed 2020-05-05 | 1.34M shares derived: sum of 4 quarters · filed 2020-05-05 |
| 2020-01-03 | 268.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 509.83K shares derived: sum of 2 quarters · filed 2020-02-25 | 1.06M shares derived: sum of 3 quarters · filed 2020-02-25 | 1.31M shares 10-K · filed 2020-02-25 |
| 2019-09-27 | 241.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | 795.47K shares derived: sum of 2 quarters · filed 2019-10-30 | 1.04M shares 10-Q · filed 2019-10-30 | 1.26M shares derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | 554.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | 801.17K shares 10-Q · filed 2019-07-31 | 1.02M shares derived: sum of 3 quarters · filed 2019-07-31 | 3.22M shares derived: sum of 4 quarters · filed 2019-07-31 |
| 2019-03-29 | 246.82K shares 10-Q · filed 2019-05-01 | 463.18K shares derived: sum of 2 quarters · filed 2019-05-01 | 2.67M shares derived: sum of 3 quarters · filed 2019-05-01 | 3.19M shares derived: sum of 4 quarters · filed 2019-05-01 |
| 2018-12-28 | 216.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | 2.42M shares derived: sum of 2 quarters · filed 2019-02-22 | 2.94M shares derived: sum of 3 quarters · filed 2019-02-22 | 3.24M shares 10-K · filed 2019-02-22 |
| 2018-09-28 | 2.20M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | 2.73M shares derived: sum of 2 quarters · filed 2018-11-01 | 3.02M shares 10-Q · filed 2018-11-01 | 4.37M shares derived: sum of 4 quarters · filed 2018-11-01 |
| 2018-06-29 | 525.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | 818.84K shares 10-Q · filed 2018-08-01 | 2.16M shares derived: sum of 3 quarters · filed 2018-08-01 | 2.31M shares derived: sum of 4 quarters · filed 2018-08-01 |
| 2018-03-30 | 293.58K shares 10-Q · filed 2018-05-02 | 1.64M shares derived: sum of 2 quarters · filed 2018-05-02 | 1.79M shares derived: sum of 3 quarters · filed 2018-05-02 | 2.17M shares derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-12-29 | 1.34M shares derived: 10-K 12 month − 3 quarters · filed 2018-02-26 | 1.49M shares derived: sum of 2 quarters · filed 2018-02-26 | 1.88M shares derived: sum of 3 quarters · filed 2018-02-26 | 2.17M shares 10-K · filed 2018-02-26 |
| 2017-09-30 | 147.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | 533.14K shares derived: sum of 2 quarters · filed 2017-11-01 | 821.26K shares 10-Q · filed 2017-11-01 | 1.25M shares derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-06-30 | 385.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | 674.11K shares 10-Q · filed 2017-08-02 | 1.10M shares derived: sum of 3 quarters · filed 2017-08-02 | 2.15M shares derived: sum of 4 quarters · filed 2017-08-02 |
| 2017-03-31 | 288.12K shares 10-Q · filed 2017-05-01 | 717.82K shares derived: sum of 2 quarters · filed 2017-05-01 | 1.76M shares derived: sum of 3 quarters · filed 2017-05-01 | 2.43M shares derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-12-31 | 429.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 1.47M shares derived: sum of 2 quarters · filed 2017-02-27 | 2.14M shares derived: sum of 3 quarters · filed 2017-02-27 | 4.20M shares 10-K · filed 2017-02-27 |
| 2016-09-30 | 1.04M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 1.71M shares derived: sum of 2 quarters · filed 2016-11-03 | 3.77M shares 10-Q · filed 2016-11-03 | 4.16M shares derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | 664.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | 2.73M shares 10-Q · filed 2016-08-03 | 3.12M shares derived: sum of 3 quarters · filed 2016-08-03 | 6.68M shares derived: sum of 4 quarters · filed 2016-08-03 |
| 2016-03-31 | 2.06M shares 10-Q · filed 2016-05-04 | 2.45M shares derived: sum of 2 quarters · filed 2016-05-04 | 6.02M shares derived: sum of 3 quarters · filed 2016-05-04 | 6.72M shares derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-12-31 | 389.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | 3.95M shares derived: sum of 2 quarters · filed 2016-02-29 | 4.66M shares derived: sum of 3 quarters · filed 2016-02-29 | 8.89M shares 10-K · filed 2016-02-29 |
| 2015-09-30 | 3.56M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | 4.27M shares derived: sum of 2 quarters · filed 2015-11-10 | 8.51M shares 10-Q · filed 2015-11-10 | 8.89M shares derived: sum of 4 quarters · filed 2015-11-10 |
| 2015-06-30 | 705.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | 4.94M shares 10-Q · filed 2015-08-11 | 5.33M shares derived: sum of 3 quarters · filed 2015-08-11 | 13.86M shares derived: sum of 4 quarters · filed 2015-08-11 |
| 2015-03-31 | 4.24M shares 10-Q · filed 2015-04-30 | 4.62M shares derived: sum of 2 quarters · filed 2015-04-30 | 13.15M shares derived: sum of 3 quarters · filed 2015-04-30 | 13.65M shares derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-12-31 | 384.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 8.92M shares derived: sum of 2 quarters · filed 2015-03-02 | 9.41M shares derived: sum of 3 quarters · filed 2015-03-02 | 10.04M shares 10-K · filed 2015-03-02 |
| 2014-09-30 | 8.53M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | 9.03M shares derived: sum of 2 quarters · filed 2014-11-04 | 9.65M shares 10-Q · filed 2014-11-04 | 10.57M shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2014-06-30 | 494.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | 1.12M shares 10-Q · filed 2014-07-31 | 2.04M shares derived: sum of 3 quarters · filed 2015-03-02 | |
| 2014-03-31 | 626.29K shares 10-Q · filed 2014-05-01 | 1.54M shares derived: sum of 2 quarters · filed 2015-03-02 | ||
| 2013-12-31 | 915.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 6.69M shares 10-K · filed 2015-03-02 | ||
| 2013-09-30 | 5.78M shares 10-Q · filed 2013-10-30 | |||
| 2012-12-31 | 3.44M shares 10-K · filed 2015-03-02 | |||
| 2011-12-31 | 2.55M shares 10-K · filed 2014-02-20 | |||
| 2010-12-31 | 243.50K shares 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |